BG
BGM.US BGM Group Ltd.
- Market cap
- USD 105M
- P/E
- -
- P/B
- 0.26x
- ROE
- -2.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is BGM.US undervalued?
Graham numberThe Graham number of BGM Group Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BGM Group Ltd. fundamental analysis
No fundamental analysis for BGM Group Ltd. yet.
BGM Group Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BGM Group Ltd.
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used b…
Full company profileBGM Group Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BGM Group Ltd. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 22.5M | 50.4M | 46.1M | 50.0M | 57.1M | 64.9M | 46.5M | 25.1M | 37.9M | 97.2M |
| Gross Profit | 3.38M | 8.13M | 9.68M | 7.54M | 5.64M | 6.23M | 1.75M | 4.11M | 4.85M | 13.4M |
| Operating Income | 1.13M | 5.97M | 6.18M | 4.81M | 2.39M | 2.10M | -2.61M | -564K | -12.6M | -3.51M |
| EBITDA | 3.38M | 7.62M | 8.35M | 7.22M | 4.15M | 3.74M | -1.27M | 880K | -11.1M | 297K |
| Net Income | 1.41M | 5.17M | 5.33M | 5.06M | 3.15M | 1.08M | -7.78M | -1.44M | -19.9M | -8.42M |
| EPS | 6.06 | 22 | 23 | 22 | 14 | 4.47 | -32 | -5.99 | -5.28 | -1.36 |
| Balance Sheet | ||||||||||
| Total Assets | 33.4M | 33.3M | 35.3M | 48.1M | 75.4M | 64.5M | 51.3M | 53.0M | 434M | 437M |
| Total Liabilities | 19.7M | 15.6M | 12.6M | 19.3M | 18.7M | 9.56M | 6.91M | 8.91M | 41.7M | 36.6M |
| Shareholders' Equity | 11.2M | 15.3M | 19.9M | 26.1M | 54.9M | 53.1M | 42.8M | 42.7M | 391M | 398M |
| Cash & Short-term Investments | 5.37M | 5.28M | 4.59M | 11.9M | 10.5M | 14.3M | 22.4M | 18.1M | 10.8M | 11.5M |
| Total Debt | 6.94M | 4.22M | 4.90M | 7.59M | 8.03M | 1.77M | 578K | - | 1.94M | 1.18M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 2.68M | 4.44M | -580K | 5.08M | 345K | 12.7M | 312K | 544K | -2.37M | 9.95M |
| Capital Expenditure | 1.53M | 1.12M | 617K | 459K | 3.49M | 3.26M | 3.71M | 3.93M | 2.07M | 2.66M |
| Free Cash Flow | 1.15M | 3.32M | -1.20M | 4.62M | -3.15M | 9.40M | -3.40M | -3.39M | -4.44M | 7.30M |
| Ratios | ||||||||||
| ROE | 12.6% | 33.7% | 26.8% | 19.4% | 5.7% | 2.0% | -18.2% | -3.4% | -5.1% | -2.1% |
| ROA | 4.2% | 15.5% | 15.1% | 10.5% | 4.2% | 1.7% | -15.2% | -2.7% | -4.6% | -1.9% |
| Net Profit Margin | 6.3% | 10.3% | 11.6% | 10.1% | 5.5% | 1.7% | -16.7% | -5.7% | -52.6% | -8.7% |
| Debt to Equity | 0.62x | 0.28x | 0.25x | 0.29x | 0.15x | 0.03x | 0.01x | - | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BGM Group Ltd. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Feb 27, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 1.79M | 7.42 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 734K | 3.15 | 14.2% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:30 on Oct 1, 2026.
Who owns BGM Group Ltd.
- Insiders 38.05%
- Institutions 0.05%
- Public & others 61.90%
- Shares outstanding 12.7M
- Free float 4.63M
Top funds holding BGM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 36.3K | 0.01% | 0.00% | Aug 2026 |
| Fidelity Nasdaq Composite ETF | 2.09K | 0.02% | 0.00% | Oct 2026 |
Top institutions holding BGM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Geode Capital Management, LLC | 98.5K | 0.02% | +109.69% | Jun 2026 |
| XTX Topco Ltd | 63.1K | 0.02% | +451.62% | Jun 2026 |
| UBS Group AG | 57.6K | 0.01% | +2,853.18% | Jun 2026 |
| Jane Street Group LLC | 57.2K | 0.01% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 54.2K | 0.01% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 32.1K | 0.01% | +103.77% | Jun 2026 |
| Ground Swell Capital, LLC | 11.1K | 0.00% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 1.82K | 0.00% | -8.47% | Jun 2026 |
| Royal Bank of Canada | 1.50K | 0.00% | -25.27% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 200.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 9.00 | 0.00% | +200.00% | Jun 2026 |
| Rockefeller Capital Management L.P. | 5.00 | 0.00% | 0.00% | Jun 2026 |
| State Street Corp | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| GSA Capital Partners LLP | 0.00 | 0.00% | -100.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| HRT FINANCIAL LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
BGM Group Ltd. company profile
- Company name
- BGM Group Ltd.
- Ticker
- BGM.US
- ISIN
- KYG7307E1237
- Exchange
- USA Stocks
- Listed since
- Aug 12, 2024
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 298
- Fiscal year end
- September
- Address
- No.152 Hongliang East 1st Street, Chengdu, China, 610200
- Phone
- 86 28 6477 5180
- Website
- bgmgroupltd.com
About BGM Group Ltd.
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.
BGM Group Ltd. management
3- Ms. Huandi ZhaoCo-Chief Executive Officer & Director · born 1985
- Ms. Li HongCo-Chief Executive Officer
- Ms. Yaxuan ZhaiChief Financial Officer · born 1995